Multiple Myeloma Posts on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

Evaluating bortezomib consolidation or maintenance for patients with multiple myeloma

Posted by on Mar 19, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of consolidation and maintenance regimens containing bortezomib (Velcade) for multiple myeloma (MM). This study concluded that consolidation therapy with bortezomib improved survival without tumor growth or spread. Some background Multiple myeloma is a type of cancer of the bone...

Read More

The effects of daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma

Posted by on Feb 29, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effects of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan (Alkeran), and prednisone (Deltasone) among patients with newly diagnosed multiple myeloma who are not candidates for transplant. The main finding was that this regimen safely improved survival in such patients. Some...

Read More

Does levofloxacin prophylaxis help in patients with newly diagnosed myeloma?

Posted by on Jan 25, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of levofloxacin (Levaquin) treatment for the prevention of infections among patients with newly diagnosed myeloma. The main finding was that levofloxacin treatment reduced fever and death during the first 12 weeks of myeloma therapy. Some background Myeloma is a cancer that affects...

Read More

Evaluating isatuximab for patients with recurrent or non-responding multiple myeloma

Posted by on Jan 8, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study examined the effectiveness and safety of isatuximab plus PD (pomalidomide, dexamethasone) for patients with multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that isatuximab was well-tolerated and significantly improved survival outcomes for these patients. Some...

Read More

My Oncologist Doesn’t Believe Food Is Necessary

My Oncologist Doesn’t Believe Food Is Necessary

Posted by on Dec 3, 2019 in Blog, Breast cancer, Colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...

Read More

Looking for patients with newly diagnosed multiple myeloma to test a combination therapy

Posted by on Oct 31, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study is evaluating the safety and effectiveness of the D-KRd regimen (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in patients with multiple myeloma. The main outcome to be measured will be the number of patients who respond to treatment. This study is recruiting in Chicago, Illinois. The details Multiple myeloma (MM)...

Read More

Evaluating lenalidomide-based regimens for elderly patients with multiple myeloma

Posted by on Oct 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study compared different treatment combinations for first-line and maintenance therapies in elderly patients with multiple myeloma (MM). The authors found that first-line MPR was most effective for fit elderly patients, while all patients benefitted from RP maintenance therapy. Some background MM is a complex disease, and...

Read More

Evaluating outcomes in patients with multiple myeloma after RVD therapy followed by stem cell transplant outside of clinical trials

Posted by on Oct 13, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the safety and effectiveness of RVD (lenalidomide, bortezomib, dexamethasone) in patients with multiple myeloma before a stem cell transplant (SCT) in a real-life setting (outside of clinical trials). This study concluded that this treatment was safe and effective for these patients. Some background Multiple myeloma...

Read More

Can levels of immune cells predict the outcomes of SCT for patients with multiple myeloma?

Posted by on Oct 9, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study examined if the numbers of different immune cells before and after a stem cell transplant (SCT) predicted treatment outcomes for patients with multiple myeloma (MM). The authors concluded that the numbers of two types of immune cells and antibody levels were associated with a successful transplant. Some background MM...

Read More